Drugmaker Roche Holding AG expects results from 19 late-stage clinical trials over the next 18 months, providing a stream of products to offset a potential near-term threat to breast cancer drug Herceptin, its third biggest seller
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment